We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

This study has been withdrawn prior to enrollment.
(Drug supply unavailable)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00310128
First Posted: April 3, 2006
Last Update Posted: February 3, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
AIDS Malignancy Consortium
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: No date given
  Primary Completion Date: No date given